Ribupatide
To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese
Fujian Shengdi Pharmaceutical Co · Phase 3 · Completed · Enrollment 567
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Treatment group A: HRS9531 injection | Obesity or overweight | n/r | n/r | n/r | n/r |
| Treatment group B: HRS9531 injection | Obesity or overweight | n/r | n/r | n/r | n/r |
| Treatment group C: HRS9531 injection | Obesity or overweight | n/r | n/r | n/r | n/r |
| Placebo injection | Obesity or overweight | n/r | n/r | n/r | n/r |